Patents by Inventor Zuwen ZHOU

Zuwen ZHOU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS AS PROTEIN KINASE INHIBITORS
    Publication number: 20230174556
    Abstract: Provided are certain PI3K inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: May 14, 2021
    Publication date: June 8, 2023
    Inventors: Zuwen ZHOU, Rui TAN, Hua XU, Qihong LIU, Huajie ZHANG, Bin LIU, Weipeng ZHANG, Zhifu LI, Yanxin LIU, Shu LIN, Xingdong ZHAO, Weibo WANG
  • COMPOUNDS AS BCL-2 INHIBITORS
    Publication number: 20230159527
    Abstract: Provided are certain Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: May 7, 2021
    Publication date: May 25, 2023
    Inventors: Weipeng ZHANG, Hongbin LIU, Rui TAN, Zhifu LI, Yue RONG, Qihong LIU, Zhifang CHEN, Ling CHEN, Hua XU, Zuwen ZHOU, Jinhua YU, Haohan TAN, Bin LIU, Yunling WANG, Lijun YANG, Chengxi HE, Lihua JIANG, Shu LIN, Xingdong ZHAO, Weibo WANG
  • APOPTOSIS-INDUCING AGENTS
    Publication number: 20220402913
    Abstract: Provided are certain Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: July 15, 2021
    Publication date: December 22, 2022
    Inventors: Hongbin LIU, Yue RONG, Huajie ZHANG, Zhifang CHEN, Rui TAN, Chengxi HE, Zhifu LI, Zuwen ZHOU, Haohan TAN, Kai RAN, Xianlong WANG, Zongyao ZOU, Lihua JIANG, Yanxin LIU, Xingdong ZHAO, Weibo WANG, Jiemin FU
  • HETEROCYCLIC DERIVATIVES AND USE THEREOF
    Publication number: 20220354860
    Abstract: Provided are certain URAT1 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: June 15, 2020
    Publication date: November 10, 2022
    Inventors: Zuwen ZHOU, Hua XU, Yue RONG, Ling CHEN, Zhifang CHEN, Rui TAN, Lijun YANG, Xianlong WANG, Haohan TAN, Bin LIU, Chenglin ZHOU, Yuwei GAO, Lihua JIANG, Shu LIN, Xingdong ZHAO, Weibo WANG
  • Substituted 2-azabicyclo[3.1.0]hexanes as TRK kinases inhibitors
    Patent number: 11459332
    Abstract: Provided are certain TRK inhibitors of formula (I): pharmaceutical compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: October 4, 2022
    Assignee: Fochon Biosciences, Ltd.
    Inventors: Hongbin Liu, Haohan Tan, Chengxi He, Xianlong Wang, Qihong Liu, Zhifu Li, Zuwen Zhou, Yuwei Gao, Lihua Jiang, Li Linghu, Shu Lin, Xingdong Zhao, Weibo Wang
  • SUBSTITUTED PYRROLO [2, 3-b] PYRIDINE AND PYRAZOLO [3,4-b] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
    Publication number: 20220235049
    Abstract: Provided are certain BTK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: June 1, 2020
    Publication date: July 28, 2022
    Inventors: Haohan TAN, Qihong LIU, Bin LIU, Zhifu LI, Xianlong WANG, Zuwen ZHOU, Weipeng ZHANG, Yunling WANG, Chenglin ZHOU, Yuwei GAO, Lihua JIANG, Yanxin LIU, Zongyao ZOU, Shu LIN, Kai YU, Tongshuang LI, Xingdong ZHAO, Weibo WANG
  • SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
    Publication number: 20220041588
    Abstract: Provided are certain RET inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: September 26, 2019
    Publication date: February 10, 2022
    Inventors: Chengxi HE, Rui TAN, Zuwen ZHOU, Weipeng ZHANG, Yunling WANG, Qihong LIU, Xingdong ZHAO, Yanxin LIU, Yuwei GAO, Shu LIN, Weibo WANG
  • Apoptosis-inducing agents
    Patent number: 11091478
    Abstract: Provided are certain Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: August 17, 2021
    Assignee: Fochon Pharmaceutical Co., Ltd.
    Inventors: Hongbin Liu, Yue Rong, Huajie Zhang, Zhifang Chen, Rui Tan, Chengxi He, Zhifu Li, Zuwen Zhou, Haohan Tan, Kai Ran, Xianlong Wang, Zongyao Zou, Lihua Jiang, Yanxin Liu, Xingdong Zhao, Weibo Wang, Jiemin Fu
  • Compounds as BLC-2-selective apoptosis-inducing agents
    Patent number: 11053239
    Abstract: Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof are provided. In particular, Bcl-2 inhibitors of formula (I) are provided, wherein the variable groups are as defined in the specification. The Bcl-2 inhibitors can be used to treat cell proliferative disorders.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: July 6, 2021
    Assignee: Fochon Pharmaceuticals, Ltd.
    Inventors: Xingdong Zhao, Zuwen Zhou, Chengxi He, Zhifu Li, Yue Rong, Rui Tan, Huajie Zhang, Hongbin Liu, Weipeng Zhang, Haohan Tan, Zhifang Chen, Lihua Jiang, Yanxin Liu, Min Lin, Jing Sun, Weibo Wang
  • SUBSTITUTED (2-AZABICYCLO[3.1.0]HEXAN-2-YL)PYRAZOLO[1,5-a]PYRIMIDINE AND IMIDAZO[1,2-b]PYRIDAZINE COMPOUNDS AS TRK KINASES INHIBITORS
    Publication number: 20210024528
    Abstract: Provided are certain TRK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: March 13, 2019
    Publication date: January 28, 2021
    Inventors: Hongbin LIU, Haohan TAN, Chengxi HE, Xianlong WANG, Qihong LIU, Zhifu LI, Zuwen ZHOU, Yuwei GAO, Lihua JIANG, Li LINGHU, Shu LIN, Xingdong ZHAO, Weibo WANG
  • Indolizine derivatives, composition and methods of use
    Patent number: 10894038
    Abstract: Provided are certain URAT1 inhibitors, pharmaceutical compositions thereof, and methods of use therefor.
    Type: Grant
    Filed: December 26, 2016
    Date of Patent: January 19, 2021
    Assignees: SHANGHAI FOCHON PHARMACEUTICAL CO. LTD., FOCHON PHARMACEUTICALS, LTD.
    Inventors: Tongshuang Li, Xingdong Zhao, Chuiliang Yu, Haohan Tan, Xianlong Wang, Rui Tan, Bin Liu, Weipeng Zhang, Huajie Zhang, Qihong Liu, Zuwen Zhou, Zhifu Li, Yue Rong, Jing Sun, Weibo Wang
  • Certain protein kinase inhibitors
    Patent number: 10835535
    Abstract: Certain CDK4/6 inhibitors and pharmaceutically acceptable salts thereof are described. In particular, these compounds can inhibit kinase activity of CDK4/6 and may be useful for the treatment of hyper-proliferative diseases like cancer and inflammation. In addition, the pharmaceutical compositions thereof and methods of use thereof are also described.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: November 17, 2020
    Assignees: Shanghai Fochon Pharmaceutical Co., Ltd., Fochon Pharmaceuticals, Ltd.
    Inventors: Xingdong Zhao, Tongshuang Li, Zhifang Chen, Rui Tan, Ling Chen, Xianlong Wang, Lijun Yang, Zuwen Zhou, Yanxin Liu, Min Lin, Jing Sun, Weibo Wang
  • APOPTOSIS-INDUCING AGENTS
    Publication number: 20200115379
    Abstract: Provided are certain Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: April 17, 2018
    Publication date: April 16, 2020
    Inventors: Hongbin LIU, Yue RONG, Huajie ZHANG, Zhifang CHEN, Rui TAN, Chengxi HE, Zhifu LI, Zuwen ZHOU, Haohan TAN, Kai RAN, Xianlong WANG, Zongyao ZOU, Lihua JIANG, Yanxin LIU, Xingdong ZHAO, Weibo WANG, Jiemin FU
  • INDOLIZINE DERIVATIVES, COMPOSITION AND METHODS OF USE
    Publication number: 20200113876
    Abstract: Provided are certain URAT1 inhibitors, pharmaceutical compositions thereof, and methods of use therefor.
    Type: Application
    Filed: December 26, 2016
    Publication date: April 16, 2020
    Inventors: Tonshuang LI, Xingdong ZHAO, Chuiliang YU, Haohan TAN, Xianlong WANG, Rui TAN, BIN LIU, Weipeng ZHANG, Huajie ZHANG, Qihong LIU, Zuwen ZHOU, Zhifu LI, Yue RONG, Jing SUN, Weibo WANG
  • COMPOUNDS AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS
    Publication number: 20190345156
    Abstract: Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof are provided. In particular, Bcl-2 inhibitors of formula (I) are provided, wherein the variable groups are as defined in the specification. The Bc1-2 inhibitors can be used to treat cell proliferative disorders.
    Type: Application
    Filed: January 5, 2018
    Publication date: November 14, 2019
    Applicants: Shanghai Fochon Pharmaceutical Co., Ltd., Fochon Pharmaceuticals, Ltd.
    Inventors: Xingdong ZHAO, Zuwen ZHOU, Chengxi HE, Zhifu LI, Yue RONG, Rui TAN, Huajie ZHANG, Hongbin LIU, Weipeng ZHANG, Haohan TAN, Zhifang CHEN, Lihua JIANG, Yanxin LIU, Min LIN, Jing SUN, Weibo WANG
  • Certain protein kinase inhibitor
    Patent number: 10450316
    Abstract: Provided are certain CDK4/6 inhibitors with the structure of formula (I), pharmaceutical compositions thereof, and methods of use therefor. The compounds are of the class of pyrimidin-2 amine derivatives, useful for the treatment of hyper-proliferative diseases.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: October 22, 2019
    Assignees: CHONGQING FOCHON PHARMACEUTICAL CO., LTD., SHANGHAI FOCHON PHARMACEUTICAL CO., LTD.
    Inventors: Xingdong Zhao, Tongshuang Li, Haohan Tan, Zhifang Chen, Ling Chen, Qihong Liu, Yue Rong, Lijun Yang, Xianlong Wang, Rui Tan, Zuwen Zhou, Bin Liu, Min Lin, Lihua Jiang, Yanxin Liu, Li Linghu, Jing Sun, Weibo Wang
  • CERTAIN PROTEIN KINASE INHIBITORS
    Publication number: 20190209566
    Abstract: Certain CDK4/6 inhibitors and pharmaceutically acceptable salts thereof are described. In particular, these compounds can inhibit kinase activity of CDK4/6 and may be useful for the treatment of hyper-proliferative diseases like cancer and inflammation. In addition, the pharmaceutical compositions thereof and methods of use thereof are also described.
    Type: Application
    Filed: May 5, 2017
    Publication date: July 11, 2019
    Inventors: Xingdong ZHAO, Tongshuang LI, Zhifang CHEN, Rui TAN, Ling CHEN, Xianlong WANG, Lijun YANG, Zuwen ZHOU, Yanxin LIU, Min LIN, Jing SUN, Weibo WANG
  • Certain protein kinase inhibitors
    Patent number: 10328060
    Abstract: Provided are certain PI3K inhibitors, pharmaceutical compositions thereof, and methods of use therefor.
    Type: Grant
    Filed: November 1, 2015
    Date of Patent: June 25, 2019
    Assignees: SHANGHAI FOCHON PHARMACEUTICAL CO., LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES, CHONGQING FOCHON PHARMACEUTICAL CO., LTD.
    Inventors: Xingdong Zhao, Jian Ding, Linghua Meng, Meiyu Geng, Tongshuang Li, Zuwen Zhou, Ling Chen, Qihong Liu, Xianlong Wang, Lijun Yang, Yue Rong, Rui Tan, Chuiliang Yu, Lihua Jiang, Yanxin Liu, Li Linghu, Jing Sun, Weibo Wang
  • CERTAIN PROTEIN KINASE INHIBITOR
    Publication number: 20180291027
    Abstract: Provided are certain CDK4/6 inhibitors, pharmaceutical compositions thereof, and methods of use therefor.
    Type: Application
    Filed: April 28, 2016
    Publication date: October 11, 2018
    Inventors: Xingdong ZHAO, Tongshuang LI, Haohan TAN, Zhifang CHEN, Ling CHEN, Qihong LIU, Yue RONG, Lijun YANG, Xianlong WANG, Rui TAN, Zuwen ZHOU, Bin LIU, Min LIN, Lihua JIANG, Yanxin LIU, Li LINGHU, Jing SUN, Weibo WANG
  • Quinazoline derivatives, compositions thereof, and use as pharmaceuticals
    Patent number: 10053449
    Abstract: Disclosed herein are protein kinase inhibitors, more particularly novel quinazoline derivatives and pharmaceutical compositions thereof, and method of use thereof.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: August 21, 2018
    Assignee: Shanghai Fochon Pharmaceutical Co., Ltd.
    Inventors: Weibo Wang, Xingdong Zhao, Tongshuang Li, Qiang Tian, Ling Chen, Zuwen Zhou, Zhifu Li, Xianlong Wang, Yue Rong, Lihua Jiang, Yanxin Liu, Jing Sun, Fanxin Zeng